Nephrology

FDA grants priority review to obinutuzumab, positioning it as the first potential approved therapy for primary membranous nephropathy.

This week’s headlines include the FDA acceptance of mitapivat and roflumilast applications, the approval of atacicept for IgA nephropathy, and more.

MOTheR trial data suggest expanded hemodialysis offers comparable outcomes to online hemodiafiltration for dialysis patients, Patricia de Sequera, MD, PhD explains.

Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.

The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression

Here are 7 of the biggest nephrology stories from Q2 of 2026!

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Catch up on the nephrology headlines you missed in June 2026.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Preview the biggest anticipated FDA decisions of Q3 2026, including atacicept for IgAN, mRNA flu vaccine, Furoscix ReadyFlow, and more.

Katherine Tuttle, MD, discusses shifting the goals of chronic kidney disease management from slowing progression to preserving kidney function.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

A post-hoc analysis of the STEP UP trial found that semaglutide 7.2 mg and 2.4 mg were linked to eGFR increases in adults with obesity who did not have diabetes.

The phase 3 TURING trial found rituximab slashed relapse rates in adults with minimal change disease and FSGS, offering a steroid-sparing alternative.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

Phase 2 JASMINE data show nipocalimab achieved SRI-4 response rates of 53.5% vs 46.7% with placebo at week 24, with benefits sustained through week 52.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.